Chromosomal rearrangements are implicated in the pathogenesis of several human malignancies, but, concurrently, they also represent targetable opportunities, as exemplified by imatinib (Gleevec), which targets theBCR-ABLgene fusion in myeloid leukemia. In prostate cancer, several chromosomal rearrangements have been identified, most of them involvingETSgenes, which encode key transcription factors. In this review, we explore the discovery of 5′ partners that classifyETSgene fusions into distinct groups based on the prostate specificity and androgen responsiveness. Furthermore, we try to address the relationship between gene fusion status and patient outcomes and discuss the possibility of using prostate-specific targeting ofETSgene fusions in cancer detection, stratification, and treatment.
染色体易位与多种人类恶性肿瘤的发病机制相关，但同时也为靶向治疗提供了契机，例如伊马替尼（格列卫）通过靶向髓系白血病中的BCR-ABL基因融合而成功应用。在前列腺癌中已发现多种染色体易位，其中多数涉及编码关键转录因子的ETS基因。本文综述了基于前列腺特异性与雄激素反应性对ETS基因融合5′端伴侣基因的分类研究，探讨了基因融合状态与患者预后的关联，并讨论了在前列腺癌检测、分层及治疗中特异性靶向ETS基因融合的可能性。
Oncogenic Fusions HarboringETSGenes: Exploring Novel Targetable Opportunities in Prostate Cancer
肿瘤(癌症)患者之家